Azenta, Inc. AZTA
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions. We support our customers from research and clinical development to commercialization with our sample management and automated storage systems, as well as genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples, including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, along with sample repository services. Our expertise, global footprint, and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions. In total, we employ approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2025 and have sales in approximately 95 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia and Europe.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.8M | $573.4M | $551.5M | $555.5M | $513.7M | $388.5M | $334.2M | $631.6M | $527.5M | $434.0M |
| Cost of revenue | $323.5M | $318.8M | $312.3M | $299.9M | $269.9M | $216.4M | $199.6M | $385.5M | $328.6M | $277.3M |
| Gross profit | $270.3M | $254.6M | $239.2M | $255.6M | $243.8M | $172.1M | $134.6M | $246.1M | $198.9M | $156.7M |
| R&D | $30.4M | $31.5M | $32.1M | $27.5M | $22.4M | $17.8M | $17.3M | $46.9M | $39.9M | $44.2M |
| SG&A | $261.6M | $263.0M | $263.7M | $251.5M | $252.1M | $190.3M | $163.3M | $167.0M | $141.5M | $119.3M |
| Total operating expenses | $297.1M | $305.9M | $300.5M | $280.3M | $274.9M | $208.7M | $182.0M | $214.7M | $184.6M | $173.7M |
| Operating income | -$26.8M | -$51.3M | -$61.2M | -$24.7M | -$31.1M | -$36.6M | -$47.4M | $31.4M | $14.3M | -$17.1M |
| Interest expense | — | — | — | $4.6M | $2.0M | $2.9M | $22.2M | $9.5M | $408.0K | $157.0K |
| Pre-tax income | -$7.1M | -$19.1M | -$20.0M | -$9.9M | -$49.0M | -$40.3M | -$84.0M | $20.5M | $14.5M | -$18.1M |
| Income tax | $31.6M | $5.2M | $12.0M | $1.4M | $20.1M | $13.9M | $22.8M | $47.3M | $3.4M | $66.2M |
| Net income | -$55.8M | -$164.9M | -$14.6M | $2.13B | $110.7M | $64.9M | $437.4M | $116.6M | $62.6M | -$69.5M |
| EPS, basic | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.08 | 1.65 | 0.90 | -1.01 |
| EPS, diluted | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.04 | 1.64 | 0.89 | -1.01 |
| Shares, diluted (wtd. avg.) | $45.9M | $53.2M | $66.3M | $74.9M | $74.5M | $73.8M | $72.4M | $70.9M | $70.5M | $68.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $279.8M | $280.0M | $649.5M | $658.3M | $227.4M | $250.6M | $256.6M | $197.7M | $101.6M | $85.1M |
| Short-term investments | $61.1M | $151.2M | $338.9M | $911.8M | $81.0K | $51.0K | $34.1M | $46.3M | — | — |
| Receivables | $142.2M | $154.2M | $156.5M | $163.8M | $119.9M | $94.8M | $165.6M | $125.2M | $93.5M | $106.4M |
| Inventory | $80.8M | $71.3M | $128.2M | $85.5M | $60.4M | $37.1M | $99.4M | $97.0M | $73.4M | $92.6M |
| Total current assets | $678.3M | $833.0M | $1.42B | $2.46B | $777.4M | $649.5M | $647.1M | $564.1M | $351.8M | $299.3M |
| Property, plant and equipment | — | — | — | — | — | — | $100.7M | $60.0M | $57.0M | $54.9M |
| Goodwill | $702.4M | $691.4M | $675.4M | $513.6M | $469.4M | $453.2M | $440.8M | $255.9M | $207.2M | $175.7M |
| Other intangibles | $101.8M | $125.0M | $294.3M | $178.4M | $186.5M | $212.3M | $251.2M | $100.0M | $83.5M | $81.8M |
| Total assets | $2.02B | $2.10B | $2.89B | $3.72B | $1.82B | $1.56B | $1.52B | $1.10B | $766.6M | $685.9M |
| Accounts payable | $38.3M | $33.3M | $35.8M | $38.7M | $42.4M | $25.7M | $58.9M | $44.7M | $49.1M | $41.1M |
| Short-term debt | — | — | — | — | — | $827.0K | $829.0K | $2.0M | — | — |
| Total current liabilities | $246.2M | $206.1M | $210.9M | $230.5M | $345.1M | $211.1M | $272.3M | $164.6M | $146.8M | $119.8M |
| Long-term debt | — | — | — | — | $49.7M | $49.6M | $50.3M | $194.1M | — | — |
| Total liabilities | $346.0M | $332.4M | $351.2M | $352.7M | $494.2M | $345.7M | $377.0M | $377.4M | $159.0M | $132.2M |
| Retained earnings | $1.37B | $1.48B | $1.64B | $1.66B | -$470.1M | -$551.1M | -$586.4M | -$994.1M | -$1.08B | -$1.12B |
| Total equity | $1.67B | $1.77B | $2.53B | $3.36B | $1.33B | $1.21B | $1.14B | $717.8M | $607.6M | $553.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $72.2M | $49.7M | $5.8M | -$466.0M | $149.9M | $37.9M | $90.9M | $74.0M | $96.2M | $39.5M |
| Depreciation and amortisation | $32.0M | $29.7M | $29.3M | $21.9M | $19.5M | $18.7M | $14.0M | $12.5M | $10.1M | $12.2M |
| Stock-based compensation | $20.9M | $14.5M | $9.4M | $10.7M | $27.5M | $16.3M | $20.1M | $19.8M | $17.3M | $11.7M |
| Capital expenditure | $33.9M | $37.4M | $39.4M | $73.4M | $52.8M | $39.9M | $23.9M | $12.8M | $12.7M | $12.8M |
| Investing cash flow | -$90.5M | $224.7M | $431.4M | $1.47B | -$146.3M | -$22.7M | $211.3M | -$148.5M | -$54.2M | -$10.9M |
| Financing cash flow | -$9.6M | -$659.2M | -$840.5M | -$62.8M | -$25.9M | -$27.0M | -$191.2M | $170.3M | -$25.9M | -$26.0M |
| Dividends paid | — | $0 | $0 | $7.5M | $29.7M | $29.5M | $28.9M | $28.3M | $27.9M | $27.5M |
| Buybacks | $0 | $661.7M | $838.5M | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-036931.
Others in SIC 3559
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LRCX | LAM RESEARCH CORP | $384.97B | 53.4x | 26.0% |
| ACMR | ACM Research, Inc. | $5.05B | 54.3x | 15.2% |
| ACLS | AXCELIS TECHNOLOGIES INC | $3.55B | 30.3x | -17.6% |
| VECO | VEECO INSTRUMENTS INC | $2.73B | 75.7x | -7.4% |
| CRCT | Cricut, Inc. | $1.16B | 15.8x | -0.5% |
| ERII | Energy Recovery, Inc. | $389.5M | 18.2x | -6.9% |
| VELO | Velo3D, Inc. | $373.3M | — | 12.1% |
| ASYS | AMTECH SYSTEMS INC | $261.7M | — | -21.6% |